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Abstract
Background—Cervical cancer is a major public health problem in resource-limited settings,
particularly among HIV-infected women. Given the challenges of cytology-based approaches, the
efficiency of new screening programs need to be assessed.
Setting—Community and hospital-based clinics in Gaborone, Botswana.
Objective—To determine the feasibility, and efficiency of the “See and Treat” approach using
Visual Inspection Acetic Acid (VIA) and Enhanced Digital Imaging (EDI) for cervical cancer
prevention in HIV-infected women.
Methods—A two-tier community-based cervical cancer prevention program was implemented.
HIV-infected women were screened by nurses at the community using the VIA/EDI approach.
Low-grade lesions were treated with cryotherapy on the same visit.
Women with complex lesions were referred to our second tier, specialized clinic for evaluation.
Weekly quality control assessments were performed by a specialist in collaboration with the
nurses on all pictures taken.
Results—From March 2009 through January 2011, 2,175 patients were screened for cervical
cancer at our community-based clinic. 253 (11.6%) were found to have low-grade lesions and
received same-day cryotherapy. 1,347 (61.9%) women were considered to have a normal
examination and 575 (27.3%) were referred for further evaluation and treatment. Of the 1,347
women initially considered to have normal exams, 267 (19.8%) were recalled based on weekly
quality control assessments. 210 (78.6%) of the 267 recalled women and 499 (86.8%) of the 575
referred women were seen at the referral clinic. Of these 709 women, 506 (71.4%) required
additional treatment. Overall, 264 CIN stage 2 or 3 were identified and treated, and six micro-
invasive cancers identified were referred for further management.
Conclusions—Our “See and Treat” cervical cancer prevention program using the VIA/EDI
approach is a feasible, high-output and high-efficiency program, worthy of considering as an
additional cervical cancer screening method in Botswana, especially for women with limited
access to the current cytology-based screening services.
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INTRODUCTION
An estimated 16 million women are infected with HIV worldwide, with the majority living
in Sub-Saharan Africa1. Cervical cancer is a preventable disease caused by human papilloma
virus (HPV), and is a leading cause of cancer deaths among women in low-income
countries1–4. In spite of the large burden of disease, only 20–40% of HIV-infected women
are screened for cervical cancer. Although 10–30% are found to have lesions requiring
treatment, less than 10% receive appropriate therapy1,2,5–7. The reasons behind the failure to
implement effective cervical cancer prevention programs in HIV-infected women are
multiple. Prevention of cervical cancer requires widespread screening, accurate diagnosis of
precursor lesions, appropriate triaging and therapy1,7. Cervical cytology, the screening test
most commonly used in developed countries, requires multiple visits by clients, screening at
regular intervals because of low sensitivity, and excellent laboratory infrastructure,
including cytology and pathology6,8–11. Cervical cancer prevention programs targeting HIV-
infected women face the additional challenge of identifying and treating a disease that
appears to have a more rapid progression and higher rates of recurrences than in the general
population12–15.
Prevalence rates for HIV in Botswana are currently approximately 28% in women in the 15–
49 age group16–19. By extrapolation, a large proportion of Batswana women can be assumed
to be at increased risk of pre-cervical cancer lesions and possible invasive cervical cancer,
thus making this a significant public health concern in Botswana20,21. Like in many
resource-limited settings, medical and technical resources are strained in Botswana,
resulting in challenges in cytology-based screening1,7.
Visual inspection with acetic acid (VIA) has recently emerged as an inexpensive, practical
alternative to cytology-based screening5,11,22–27. Application of 4 or 5% acetic acid to the
cervix results in dysplastic and neoplastic epithelium transiently appearing white, with
normal cervical squamous epithelium assuming a pink colour. VIA is more sensitive but less
specific than the Pap smear, with estimated sensitivity of 66–99% or 55–90%, and
specificity of 64–98% or 65–92%5,6,11,24,25,28. VIA can be performed by midwives, nurses
and other health care workers, which decreases barriers regarding staff shortages26,29–32.
Women with abnormal Pap smears or VIA results generally are referred for colposcopy,
which includes magnified visual inspection of the cervix after application of acetic acid.
Colposcopy has been extremely successful as a diagnostic modality for cervical pre-cancer
lesions and provides increased sensitivity compared with VIA5,27. However, use of this
technology in developing nations is severely limited by the cost of the colposcope1. To
overcome this limitation, lower-cost methods to provide easily interpretable, magnified
images of the cervix were developed. One such method is cervicography in which the cervix
is inspected through magnified photographic images1,27. Cervicography has been shown in
multiple studies to be a reliable method of detecting precancerous cervical lesions25,28,33.
Digital cameras have the advantage of easy portability and relative cost-effectiveness
compared with colposcopy. These cameras have been shown to produce quality, high
resolution images, which may be used to perform magnified examination of the cervix and
vagina (enhanced digital imaging, EDI)27,30,31,34.
To take advantage of the potential benefits of VIA/EDI, we implemented a two-tier
community-based cervical cancer prevention program for HIV-infected women in
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Botswana. We describe the program and report the outcomes of the first 23 months (March
2009 through January 2011) of its implementation.
DESIGN AND METHODS
Training
The initial phase of this program required training of staff in VIA/EDI and cryotherapy
(“See and Treat”)1. As part of on-going capacity building other health practitioners were
also trained. The community-based clinic was located at a primary clinic in Gaborone, the
capital city. HIV antiretroviral therapy and minimal access to cytology-based screening was
available at this clinic prior to our pilot. All providers were licensed nurses or nurse-
midwives who were trained to perform VIA, EDI and cryotherapy. Nurses were chosen as
the program’s primary providers because they are more available than physicians in
Botswana, and many are familiar with performing pelvic exams and function independently
in clinic settings. A three-day didactic training session took place in Zambia in January
2009, where a similar project has been running since 2006. Following the didactic training,
nurses spent two weeks in clinics gaining hands-on experience in VIA, EDI, cryotherapy,
and indications for referral, under the guidance of the Zambian team. The training continued
for six weeks in Botswana under the guidance of our program gynaecologist. At the end of
the practicum, each nurse had successfully performed a minimum of 100 VIA examinations,
100 EDI photographs, and 35 cryotherapies.
Patient population
The community clinic was set up within the same facility that has an Adult HIV clinic as
part of the National HIV program. The HIV clinic acted as a referral centre for five other
local clinics. Both men and women were referred to this clinic once tested positive for HIV.
The services provided at this clinic include assessment for initiation of HIV treatment,
follow up of HIV infected adults from the catchment area both on treatment, and those not
needing treatment yet. Any HIV-infected woman enrolled in this clinic who self-referred or
was referred by a health care worker, and chose to have cervical cancer screening at our
clinic, was cared for in our program.
Procedures at the community-based clinic
Women presenting to the “See and Treat” clinic were counselled regarding cervical cancer
prevention and consented to allow cervical photography, and cryotherapy if needed. During
speculum inspection, women were assessed for lesions suspicious of cervical cancer (raised,
ulcerative lesions with contact bleeding, bizarre blood vessel patterns); these were referred
to the tertiary hospital immediately. Women were also assessed for sexually transmitted
infections, and appropriate national treatment guidelines followed. VIA using white
household vinegar was immediately followed by EDI with a digital camera, and the results
were categorized as positive based on:
1. Observation of a well-defined, opaque aceto-white area close to the squamous-
cervical junction
2. Observation of dense aceto-whitening of a cervical growth
VIA-negative women were offered reassurance. Cryotherapy at the community-based clinic
was only performed on women diagnosed with low-grade lesions meeting all of the
following criteria:
1. An opaque lesion involving less than 3 quadrants of the transformation zone
2. No extension of the lesion into the endocervical canal or onto the vaginal wall
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3. The entire lesion could be covered by the cryotherapy probe
4. No clinical evidence of severe lesion or invasive cancer
Cryotherapy was performed using liquid nitrogen and a 15 to 24 mm ectocervical cryoprobe
tip (probe size varied depending on lesion size) with a shallow nipple. A single freeze for
seven minutes was applied. No local anaesthesia or analgesics were used prior to the
procedure. Women with abnormal VIA or EDI that did not meet the criteria for immediate
treatment were referred to our colposcopy/loop electrosurgical excision procedure (LEEP)
clinic at the Princess Marina Hospital for further evaluation.
Colposcopy and treatment of pre-cancerous lesions
Colposcopy was performed in women with high grade lesions according to VIA/EDI, or
those whose lesions were inappropriate for cryotherapy. Unlike in traditional colposcopy
examination, punch biopsies were not obtained from abnormal areas on the cervix. The “See
and Treat” approach was followed here as well, with lesions either treated with LEEP or
cautery.
Women with extensive lesions reaching the vaginal wall were referred to the gynaecology
department for cone biopsy or hysterectomy. Excised tissue specimens were processed in the
pathology laboratory. Women were given home-care instructions, asked to avoid sexual
intercourse for six weeks, and instructed to return to the clinic if they had fever for more
than two days, were passing blood clots or had severe lower abdominal pain. Women with
suspected invasive cancer were referred to the Gynaecology Department at the Princess
Marina Hospital for surgery and/or radiotherapy.
Quality Control and Nursing Education
Weekly, nurses participated in an EDI quality-control meeting that involved reviewing all
images of cervigrams from the prior week on a large screen using a projector. Discrepancies
between the nurse and the gynaecologist expert consultant were assessed with the final
decision based on the opinion of the gynaecologist. Weekly reviews included an analysis of
the correlation between the digital image and histology if available, as a means of increasing
the understanding of the myriad visual manifestations of cervicitis, squamous metaplasia,
nabothian gland cysts, endocervical polyps, glandular hyperplasia, cervical hyperplasia,
keratosis, CIN1/HPV, CIN2, CIN3, microinvasive cancer, and invasive cancer.
Data and statistical analysis
Data entry was performed at the treatment site using Access, while data analysis was carried
out using STATA 11.0. Comparisons were performed using a Mann-Whitney or Student’s t
test according to the distribution of the variables. The sensitivity, specificity, negative and
positive predictive values of nurse’s assessments were calculated using the gynaecologist
evaluation as the gold standard. In addition, inter- and intra-subject variability was
determined by asking the nurses to diagnose a selected set of 100 high-quality pictures from
our patients. Pictures showing normal and abnormal cervixes were included in the set and
the answers were not provided to the nurses. We used the gynaecologist diagnosis (for
normal cervix and low grade lesions requiring cryotherapy but not referral) and pathology
(for an abnormal cervix). The test was administered 2 weeks later showing the same set of
pictures in a different order. Intra- and inter-subject variability was calculated using the
kappa coefficient.
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This was set up as a public health care program to provide service, with a monitoring and
evaluation component. The Health Research and Development Committee of the Botswana
Ministry of Health approved the program protocol and data collection for programmatic
evaluation, including consent for imaging.
RESULTS
During the first 23 months 2175 HIV-infected women were evaluated (Figure 1). Our
population was included predominantly young (mean age 34.9, 95% confidence interval
[CI], 34.6 – 35.2) single women from lower socio-economical strata (as indicated by their
average monthly household income; Table 1). The average CD4 T cell count was 405 cells/
mm2 and the 68.8% of the women were on anti-retroviral therapy (ART).
Two hundred and fifty three of 2,175 women screened (11.6%) were found to have low-
grade lesions and received same-day cryotherapy. 1,347 (61.9%women were considered to
have a normal examination and 575 (27.3%were referred for further treatment (Figure 1). Of
the 1,347 women initially considered to have normal exams, 267 (19.8%were recalled when
the gynaecologist was unable to confirm the initial decision of the nurse either because the
images were of poor quality (68, 25.6%; Table 2) or because a possible lesion could not be
excluded (199, 74.4%; Table 2). Thus, a total of 1333 (1,347 + 253 – 267) (61.3%women
received appropriate same-day screening and treatment without the need for recall or
referral. 210 (78.6%) of the 267 recalled, and 499 (86.8%of the 575 referred women were
seen at the referral clinic (overall follow up 709 of 842, 84.2%). Reasons for recall and
referral are shown in Table 2.
Five Hundred and six (71.4% of the 709 women; 210 recall plus 499 referred) required
treatment. None of the women recalled were found to have high grade lesions (Tables 2 and
3). Overall, our program identified and treated 264 pre-cancerous lesions (CIN 2 or 3), and
identified six micro-invasive cancers which were referred for further management (Tables 2
and 3).
Of the 210 women that were recalled and followed-up by the time of this analysis, 164
required no treatment and 25 required cryotherapy/cautery. Tissue was obtained from 46
other recalled women and results were available on 12 of them, all of whom showed
changes compatible with CIN1 lesions. Of the 460 women who were referred and followed-
up, 39 required no treatment and 32 underwent cryotherapy/cautery for low-grade lesions.
Of the 319 remaining ones who were referred and had pathological results by the time of
analysis, 49 had CIN1, 62 had CIN2, 202 had CIN 3 and 6 had micro-invasive cancer. The
remaining 9 women had lesions unrelated to HPV infection (Table 3).
We based the calculations of the sensitivity and specificity of the program on the
performance of peripheral clinic and its capacity to appropriately identify patients that were
normal, patients that could be treated on-site and patients that needed referral. Using this
approach, the 267 patients recalled for evaluation were considered to be “undertreated” by
the first-tier of the program. Although the majority of those patients were found to have no
lesions (164 of the 210 patients who followed up), we believe our approach provides a better
understanding of the overall performance of the system. The nurses at the community-based
clinic diagnosed 1080 (1347 – 267) women were confirmed to be negative, 237 were
declared appropriately diagnosed and treated, 16 were “potentially over-treated (considered
“misdiagnosed” for the purpose of this analyses) and 575 were appropriately referred. Thus,
the sensitivity and specificity of the nurses’ assessment (and, therefore, of the first-tier of
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our program) were 75.3% (95% CI, 72.5 – 77.8%) and 98.5% (95% CI, 97.6 – 99.1%)
respectively.
The level of agreement between nurses and the gynaecologist in the evaluation of digital
pictures (agreement on 83.3% of the observations, kappa= 0.63, 95% CI 0.48 to 0.77,
p<0.01). Although there were some differences in the inter-subject agreement between
nurses (agreement on 86.5% of the observations, kappa= 0.69, 95% CI, 0.54 – 0.83, p<0.01),
the intra-subject agreement was substantially higher (agreement on 91.2% of the
observations, kappa= 0.72, 95% CI, 0.64 – 0.80, p<0.001).
DISCUSSION
Our results demonstrate that community-based “See and Treat” programs using VIA/EDI
can be valuable additions to screening programs for cervical cancer prevention in HIV-
infected women in settings like Botswana. To our knowledge, this is the first community-
based VIA/EDI screening program targeting exclusively HIV-infected women. Our
approach was efficient and had a high throughput. In addition, visualizing lesions on the
digital images by the patients serves as a form of patient education and may lead to
improved follow up rates. The digital images also allowed the implementation of quality
control measures that further improve safety34. Although a significant percentage of women
required a second visit to receive definitive treatment, the large majority of women were
able to be screened and treated on a single visit.
Consistent with our findings, digital cameras, with their advantageous portability, ease of
use, and relative cost-effectiveness, have been shown to produce quality, high resolution
images, which may be used to perform magnified examination of the cervix and vagina.
Mobile telemedicine phones with high resolution camera handset technology has the added
advantage of not requiring internet connections or electricity, and allows images to be
transmitted immediately. This “simultaneous telemedicine” technology could provide the
opportunity for evaluation by an expert at a distant location while the patient is being
evaluated in clinic34.
Our results are comparable to those reported by similar VIA-based prevention programs
from resource-limited settings1,5,29,33. Among the patients screened through our program,
only a third of women had been screened for cervical cancer by Pap smear in the past. Of
interest, the large majority of them knew their results (85%). However, in spite of
abnormalities in approximately 20%, follow up or treatment was never provided,
highlighting some of the barriers to care within cytology-based programs. The potential
benefit of treating early HPV-lesions in HIV-infected women are important advantages of
the VIA/EDI approach. Our program provided successful treatment for 85% of the patients
who needed it, a reasonable number of them on the same day. Referral for LEEP required a
second visit, but multiple visits were minimized by providing “See and LEEP”. Providing
VIA/EDI/Cryotherapy, as well as LEEP at the same facility can eliminate the need for
second visit for those patients not legible for cryotherapy.
Concerns have been raised about the safety of the See and Treat approach. In particular,
concern that lesions may be missed by nurses performing point-of-care evaluation and
treatment has limited the uptake of this approach. In our program, during the quality
assurance evaluations performed weekly, only 12% (267/2,175) of the women assessed at
the community clinic were recalled for further evaluation by the specialist. The main reason
for recall was the poor quality of the picture, or the inability to completely rule out the
possibility of a lesion by the gynaecologist based only on the picture. It is highly reassuring
that missed lesions were found only in 3.5% (7/210 who showed up) of the women recalled.
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Importantly, 164 of 210 (78%) patients recalled did not need any treatment and those that
did require treatment had either low-grade lesions (12) or other lesions (9) not related to
HPV infection.
Although we detected 264 women with CIN 2 or 3, the magnitude of the impact that such
programs will have on cervical cancer can only be established through long-term
prospective studies. The 264 pre-malignant lesions identified and treated during the 23
months of our program represent nearly 70% of all the premalignant lesions treated in the
region over the same period. “See and Treat” may offer a viable alternative to reach women
living in distant and/or underserved regions of the country (e.g. rural), while cytology-based
screening programs may still play a role in areas where the appropriate infrastructure and
human resources are available.
CONCLUSIONS
This program has shown that screening and treating women using a See-and Treat approach
of VIA/EDI followed by cryotherapy and referral for LEEP therapy is feasible, effective,
and has a significant impact on the identification and treatment of precancerous and micro-
invasive cancerous lesions in HIV-infected women in Botswana. In addition, we showed
that including telemedicine technology is feasible in these settings and could add to the
overall benefit of these programs. In resource-limited settings, “See and Treat” approaches
are highly likely to reduce the risks of a common and preventable cancer in women,
especially if both cryotherapy and LEEP can be provided at the same facility to truly allow
same day treatment for all lesions.
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Distribution of the number of HIV-infected women screened and treated by a “See-and-
Treat” cervical prevention program, Botswana 2007–2011
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